🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

RecruitingNAAges 18 Years - anyAllShahid Beheshti University of Medical Sciences
NCT07006532 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plas

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Signed written informed consent 2. eGFR\> 25 cc/min 3. Chronicity index \<8 4. IFTA\<40% 5. EBV IgG positive Exclusion Criteria: 1. Active or recurrent infections 2. History of malignancy, unless in remission for more than 2 years with no relapse 3. abnormal liver function tests 4. Platelet \< 100,000
💊

What it tests

  • Tocilizumab
📍

Where

1 site
Nooshin Dalili
Tehran, Iran
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy